Search Results - "Du, Fangyong"

Selective inhibition of type III secretion activated signaling by the Salmonella effector AvrA by Du, Fangyong, Galán, Jorge E

“…Salmonella enterica utilizes a type III secretion system (TTSS) encoded in its pathogenicity island 1 to mediate its initial interactions with intestinal…”
Get full text

Substrate-binding Sites of UBR1, the Ubiquitin Ligase of the N-end Rule Pathway by Xia, Zanxian, Webster, Ailsa, Du, Fangyong, Piatkov, Konstantin, Ghislain, Michel, Varshavsky, Alexander

“…Substrates of a ubiquitin-dependent proteolytic system called the N-end rule pathway include proteins with destabilizing N-terminal residues. N-recognins, the…”
Get full text

Experimental investigation on heat transfer characteristics of a novel hypervapotron channel for divertor target in nuclear fusion reactors by Chen, Zhen, Li, Qiang, Zhou, Zhanru, Wang, Xingli, Zhao, Bowen, Peng, Wuqingliang, Du, Fangyong, Wang, Wanjing, Yang, Zhongshi, Xu, Yuping, Huang, Shenghong, Zhou, Haishan, Luo, Guang-Nan

“…•A novel hypervapotron channel was studied for enhanced divertor target cooling.•The experiment reveals three flow regimes, comparing with traditional…”
Get full text

An Essential Role of N-Terminal Arginylation in Cardiovascular Development by Kwon, Yong Tae, Kashina, Anna S., Davydov, Ilia V., Hu, Rong-Gui, An, Jee Young, Seo, Jai Wha, Du, Fangyong, Varshavsky, Alexander

“…The enzymatic conjugation of arginine to the N-termini of proteins is a part of the ubiquitin-dependent N-end rule pathway of protein degradation. In mammals,…”
Get full text

Peptides accelerate their uptake by activating a ubiquitin-dependent proteolytic pathway by Varshavsky, Alexander, Turner, Glenn C, Du, Fangyong

“…Protein degradation by the ubiquitin system controls the intracellular concentrations of many regulatory proteins. A protein substrate of the ubiquitin system…”
Get full text

Pairs of Dipeptides Synergistically Activate the Binding of Substrate by Ubiquitin Ligase through Dissociation of Its Autoinhibitory Domain by Du, Fangyong, Navarro-Garcia, Federico, Xia, Zanxian, Tasaki, Takafumi, Varshavsky, Alexander

“…Protein degradation by the ubiquitin (Ub) system controls the concentrations of many regulatory proteins. The degradation signals (degrons) of these proteins…”
Get full text

Phase 1 study of ADG126, a novel masked anti-CTLA-4 SAFEbody, that combines tumor-localized activation with strong T reg depletion and soft ligand blocking in patients with advanced solid tumors by Richardson, Gary Edward, Tolcher, Anthony W., Morris, Michelle Frances, de Souza, Paul L., Hamid, Anis, She, Xiaohong, Zhu, Lvyu, Wang, Hongyan, Zheng, Songmao, Liu, Guizhong, Li, Yan, Du, Fangyong Felix, Fischkoff, Steven, Gong, Hua, Zha, Jiping, Luo, Peter

“…e17601 Background: SAFEbody ADG126, a masked version of NEObody ADG116 (ESMO IO Conference Abstract #394, NCT04501276), targets a unique species-conserved…”
Get full text

100 kW electron-beam high heat flux test facility for testing EAST and CFETR divertor components by Li, Qiang, Chen, Zhen, Peng, Wuqingliang, Xie, Chunyi, Wang, Wanjing, Geng, Xiang, Du, Fangyong, Zhou, Haishan, Liu, Songlin, Luo, G.-N.

“…•A 100 kW electron-beam (EB) high heat flux test facility has been constructed in ASIPP to test EAST divertor PFCs and CFETR small scale testing mock-ups.•The…”
Get full text

Assessing therapeutic window and dose selection of ADG126 (a masked anti-CTLA-4 SAFEbody): Integrating nonclinical and clinical data using mathematical modeling by Park, John J., Ariyapperuma, Mihitha, Richardson, Gary Edward, Xu, Rui-Hua, Liu, Guizhong, Chen, Xuesong, Skinner, John J., Song, Wenqing, She, Kristine Xiaohong, Zhang, Yanyan, Li, Ai, Wang, Xin, Dai, Zhengxi, Qu, Jiagui, Li, Yan, Du, Fangyong Felix, Xu, Jiangchun, Luo, Peter Peizhi, Zha, Jiping, Zheng, Songmao

“…e14518 Background: New developments have rejuvenated anti-CTLA-4 therapies, yet dose-dependent adverse events remain a core challenge, leaving dose-dependent…”
Get full text

A phase I, dose-escalation study of ADG106, a fully human anti-CD137 agonistic antibody, in subjects with advanced solid tumors or relapsed/refractory non-Hodgkin lymphoma by Zhang, Li, Zhao, Hongyun, Ma, Yuxiang, Zheng, Xin, Jiang, Ji, Zhang, Yang, Hong, Shaodong, Liu, Guizhong, She, Xiaohong, Ni, Qingjiang, Zhu, Lvyu, Zhu, Yi, Du, Fangyong Felix, Luo, Peter

“…Abstract only 3105 Background: ADG106 is a fully human agonistic anti-CD137 monoclonal IgG4 antibody, targeting a unique epitope of CD137 with novel mechanism…”
Get full text

Selective Inhibition of Type III Secretion Activated Signaling by the Salmonella Effector AvrA: e1000595 by Du, Fangyong, Galán, Jorge E

“…Salmonella enterica utilizes a type III secretion system (TTSS) encoded in its pathogenicity island 1 to mediate its initial interactions with intestinal…”
Get full text

Selective inhibition of type III secretion activated signaling by the salmonella effector AvrA by Du, Fangyong, Galan, Jorge E

“…Salmonella enterica utilizes a type III secretion system (TTSS) encoded in its pathogenicity island 1 to mediate its initial interactions with intestinal…”
Get full text

An Engineered Tetrahymena tRNAGln for in Vivo Incorporation of Unnatural Amino Acids into Proteins by Nonsense Suppression by Saks, M E, Sampson, J R, Nowak, M W, Kearney, P C, Du, F, Abelson, J N, Lester, H A, Dougherty, D A

“…A new tRNA, THG73, has been designed and evaluated as a vehicle for incorporating unnatural amino acids site-specifically into proteins expressed in vivo using…”
Get full text

Abstract A082: A phase 1, first-in-human, dose-escalation study of ADG106, a fully human anti-CD137 agonistic antibody, in subjects with advanced or metastatic solid tumors and/or relapsed/refractory non-Hodgkin lymphoma by Tolcher, Anthony, Karim, Raghad, Rosas, Christina, Liu, Guizhong, Zhu, Yi, Liu, Liming, Du, Felix Fangyong, Luo, Feng Roger, Luo, Peter

“…Abstract Background: Ligation of CD137 induces a co-stimulatory signal on activated CD8+ T cells and natural killer (NK) cells, resulting in proliferation,…”
Get full text

Development of a unique anti-CD137 therapeutic antibody: Efficacy and safety profiles in mono and combination therapy by Liu, Guizhong, Cheung, Peter, Chen, Jun, She, Xiaohong, Du, Felix Fangyong, Luo, Peter

“…Abstract only e23079 Background: Abstract: CD137 (4-1BB), a member of the TNFR super family, is expressed on several subsets of activated immune cells and acts…”
Get full text

Allosteric activation of the ubiquitin ligase UBR1 by short peptides: Molecular mechanisms and physiological functions by Du, Fangyong

“…The N-end rule relates the in vivo half life of a protein to the identity of its N-terminal residue. UBR1, the E3 of the N-end rule pathway in Saccharomyces…”
Get full text

An engineered Tetrahymena tRNA super(Gln) for in vivo incorporation of unnatural amino acids into proteins by nonsense suppression by Saks, ME, Sampson, J R, Nowak, M W, Kearney, P C, Du, Fangyong, Abelson, J N, Lester, HA, Dougherty, DA

“…A new tRNA, THG73, has been designed and evaluated as a vehicle for incorporating unnatural amino acids site-specifically into proteins expressed in vivo using…”
Get full text